The Immune Response Corporation (OTCBB: IMNR)
IRC to Discuss Upcoming Launch of Phase II NeuroVax(TM) Trial in Patients With Multiple Sclerosis; To Initiate Enrollment Before Year End
CARLSBAD, Calif.–(BUSINESS WIRE)–The Immune Response Corporation (OTCBB: IMNR – News), an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases, announced that Dr. Joseph O’Neill, President and CEO, will present an overview of the Company’s immune-based therapies, currently in Phase II clinical trials, at the Rodman & Renshaw Eighth Annual Healthcare Conference in New York City.
The Company’s presentation to the investment community will take place on Tuesday, November 7, 2006, at 3:55 p.m. (EST).
A live webcast of this presentation will be available at http://www.wsw.com/webcast/rrshq10/imnr/. The online replay will be available for 90 days after the presentation.
Dr. O’Neill will discuss a key strategic agreement, signed October 10, 2006, with Accelsiors CRO & Consultancy Services, a clinical research organization (CRO) with extensive experience in conducting multiple sclerosis (MS) trials, to oversee a 200-patient Phase IIb trial of NeuroVax(TM), an investigational T-cell receptor (TCR) peptide vaccine for the treatment of multiple sclerosis (MS). He will review in detail the Company’s drug development pipeline, and status of the Phase II clinical trials in progress for NeuroVax, and for IR103, for the treatment of human immunodeficiency virus (HIV). IR103 is based on the Company’s patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk.
“By harnessing the body’s own defenses to control disease, NeuroVax and IR103 potentially offer important clinical advances for patients suffering from MS and HIV.” said Dr. O’Neill. “We continue to make significant strides in the development of these immune based therapies and are optimistic that they may benefit the millions of patients in need of more effective and tolerable treatment options.”
About the Rodman & Renshaw Eighth Annual Healthcare Conference
The Rodman & Renshaw Eighth Annual Healthcare Conference will be held on November 6-8, 2006 at the New York Palace Hotel, New York, NY. The Conference will include presentations by over 300 companies, as well as experts from the medical, scientific and investment communities. The Conference will be attended by investors, venture capitalists, company executives, scientists and other industry leaders.
For more information about the Rodman & Renshaw Healthcare Conference in New York City, NY, please visit http://www.rodmanandrenshaw.com.
About The Immune Response Corporation
The Immune Response Corporation (OTCBB: IMNR – News) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company’s lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate disease pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax(TM), which is based on the Company’s patented T-cell receptor (TCR) peptide vaccine technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn’s disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.
IR103 is based on the Company’s patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE®, the Company’s first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com.
This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation’s SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
REMUNE® is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.
Contact:
INVESTOR
ROI Associates
Robert Giordano, 212-495-0201
rgiordano@roiny.com
or
The Immune Response Corporation
Michael K. Green, COO & CFO, 760-431-7080
info@imnr.com
Source: The Immune Response Corporation
View the StockGuru Profile for The Immune Response Corporation:
http://www.stockguru.com/profiles/imnr/
We Invite you to Visit the All New StockGuru Blog!
Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.
Click HERE to visit the Blog, or go to:
http://stockguru.com/blog/
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $50,000 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.